Advertisement

Clinical & Experimental Metastasis

, Volume 35, Issue 3, pp 87–90 | Cite as

11th International Symposium on Minimal Residual Cancer (ISMRC): 3–5 May 2018, Montpellier, France

  • Catherine Alix-Panabières
  • Klaus Pantel
Meeting report
  • 518 Downloads

International ISMRC meetings started in 1996 and have established themselves, every other year, as a premier event focusing on minimal residual cancer in patients with solid tumors. After great cities like Munich, Berlin, Oslo, San Francisco, Hamburg, Athens, Osaka and Paris, the 11th International Symposium of Minimal Residual Cancer (ISMRC) took place May 3–5 2018 at the convention center ‘Corum’ in Montpellier, France (http://www.ismrc2018.com). Forty-two international key opinion leaders and experts in the field of cancer have been invited; thirty different sponsors accepted to support this important congress and 400 participants from 31 different countries registered proposing 119 abstracts.

The 11th ISMRC has been a great opportunity to gather during 3 days, researchers and clinicians from academia and industry to share information about the most recent technical developments, clinical trials, biology discoveries and late breaking news and establish long lasting collaborations in cancer research.

The program covered multiple aspects of cancer biology with emphasis on metastasis including cancer stemness, cancer dormancy, epithelial-mesenchymal transition as well as immunomodulation of tumor cells and evolution of cancer. The translational part of the program had a specific focus on LIQUID BIOPSY in a broad sense including circulating tumor cells (CTCs), circulating nucleic acids (DNA, miRNA), exosomes and platelets with an emphasis on clinical validation studies (Fig. 1).

Fig. 1

Different topics covered by the 11th ISMRC Montpellier—France

Metastasis in cancer patients can occur after long latency periods of up to more than 10 years, a process called “cancer dormancy”. The source of these late relapses are disseminated tumor cells (DTCs) or small micrometastases undetectable by current imaging procedures. Recent advances in the development of sensitive and specific immunoassays and PCR-based technologies have made this stage of “minimal residual cancer” (MRC) become visible.

At the 11th ISMRC, international experts focusing on basic mechanisms of cancer metastasis and translational studies to detect and characterize cancer cells or their products such as nucleic acids or exosomes in the blood of cancer patients (“liquid biopsies”).

The first part of the ISMRC focused on basic mechanisms of cancer metastasis with emphasis on the early stages of tumor cell dissemination and colonization of distant organs [1, 2, 3, 4, 5]. In this context, the high plasticity of cancer cells plays an important role in metastasis [6]. Carcinoma cells can undergo an epithelial-to-mesenchymal transition (EMT) [7, 8, 9], which is associated with cancer cell stemness leading to an increased invasiveness and resistance to chemotherapy [10, 11]. EMT and cancer stem cells were therefore also the prime topics of the experts presenting their research at ISMRC [12]. Another key area of investigation was cancer dormancy, which is controlled by the features of the DTCs and the surrounding microenvironment (e.g., changes in the BM environment may induce the escape from dormancy). Most DTCs in cancer patients are initially in a dormant (i.e., non-proliferative) stage and they can display a cancer stem cell phenotype, which might help DTCs to survive systemic chemotherapy and evade immune recognition and eradication. After induction of proliferation DTCs can be eradicated by the surrounding immune cells until some mutations occur (e.g., LOH in MHC genes) that enable the DTCs to escape immuno-surveillance [13, 14]. Moreover, ‘evolutionary ecology to oncology’ was also a fascinating topic with potential crucial implications for novel treatment strategies [15].

The second part of the symposium was dedicated to clinical studies on “liquid biopsy”, a new diagnostic concept introduced in 2010 [16] for the analysis of CTCs and now extended to material (in particular DNA) released by tumor cells in the peripheral blood of cancer patients [17, 18]. Over the past decade, various methods have been developed to detect CTCs and ctDNA in the peripheral blood of cancer patients [18, 19, 20, 21]. While reliable information can be easily obtained in patients with advanced disease, early stage cancer patients usually present with very low concentrations of CTCs and ctDNA. At present, most CTC assays rely on epithelial markers and the majority of CTCs detected are single isolated cells. The clinical relevance of ‘mesenchymal’ CTCs lacking any epithelial markers as well as CTC clusters are still under investigation. Strong interests for detecting viable CTCs and for expanding them ex vivo has been highlighted in different cancer types and it remains a crucial challenge in this field of expertise. Although most published studies have been performed on patients with carcinomas and melanomas, CTCs have been also detected in the peripheral blood of patients with primary brain tumors (glioblastomas) despite the blood–brain barrier [22]. Moreover, breast cancer CTCs associated with brain metastases could be recently characterized at the molecular level [23].

Liquid biopsy assays are currently being validated for early detection of cancer, which is supposed to reduce cancer related mortality. Despite remarkable progresses, liquid biopsy-based detection of early stages of cancer remains a challenge, in particular in breast cancer. New blood-based biomarkers for early detection currently validated in clinical trials include miRNAs, exosomes and tumor-educated platelets.

In patients with diagnosed cancer, CTCs and ctDNA analyses [24] can obtain independent information on prognosis in early and advanced stages of disease. In particular, CTC counts at initial diagnosis are able to refine the current risk stratification by TNM staging in early stage breast cancer. Moreover, early detection of relapse by sequential ctDNA (or CTCs) analysis of blood samples obtained post-surgery during the follow up is possible and may be used in future trials to stratify patients to “post-adjuvant” therapies [25].

Another key application of liquid biopsy is to identify therapeutic targets or mechanisms of resistance of metastatic cells in individual patients. While the analysis of ctDNA focuses on mutations relevant for cancer therapy (e.g., EGFR, KRAS or ESR1 mutations), CTCs offer a wide spectrum of analyses at the DNA, RNA and protein levels [17, 18, 26, 27]. Metastatic cells might have unique characteristics that can differ from the bulk of cancer cells in the primary tumor currently used for stratification of patients to systemic therapy. Moreover, monitoring of CTCs and ctDNA before, during and after systemic therapy (e.g., chemotherapy, hormonal therapy, antibody therapy) might provide unique information for the future clinical management of the individual cancer patient and might serve as surrogate marker for response to therapy [28, 29, 30, 31, 32, 33, 34]. In the context of recent success in antibody-mediated blockade of immune checkpoint control molecules, expression of the PD-L1 on CTCs might be of interest as potential predictive marker [35, 36, 37, 38]. Moreover, the expression of androgen receptor variant seven in CTCs may predict resistance to anti-androgen therapy in prostate cancer, while mutations in the estrogen receptor gene (ESR1) provides information on resistance to hormone therapy in breast cancer [39, 40]. Additional therapeutic targets detected on CTCs in cancer patients include the estrogen receptor and HER-2 oncogene [18]. Single cell RNAseq analysis of CTCs may provide more comprehensive information on relevant pathways.

For functional analysis of CTCs, the development of in vitro and in vivo test systems has started, which might also serve as models for drug testing. In particular, the development of CTC lines [41] and xenografts [42, 43] derived from CTCs can provide novel insights into the biology of tumor cell dissemination and may be used to discover new pathways to target specifically metastatic cells.

Besides CTCs and ctDNA the analysis of circulating microRNAs, exosomes or tumor-educated platelets may provide complementary information as “liquid biopsy” [44]. E.g., the integrin composition of exosomes seems to determine the organ site of metastatic niches [45] and the RNA expression pattern of tumor-educated blood platelets [46] reveals information on tumors in cancer patients.

In conclusion, liquid biopsy analysis can be used to obtain new insights into metastasis biology, and as companion diagnostics to improve the stratification of therapies and to obtain insights into therapy-induced selection of cancer cells. Different approaches such as CTC or ctDNA analysis will provide complementary information [47]. Technical and clinical assay validation is very important and can be achieved in international consortia such as the European IMI Cancer-ID network (http://www.cancer-id.eu).

References

  1. 1.
    Massague J, Obenauf AC (2016) Metastatic colonization by circulating tumour cells. Nature 529(7586):298–306CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Sleeman JP (2015) Pre-metastatic conditioning of organ microenvironments by tumors: beyond preparing the soil. J Mol Med 93(11):1171–1172CrossRefPubMedGoogle Scholar
  3. 3.
    Zheng H et al (2017) Therapeutic antibody targeting tumor- and osteoblastic niche-derived jagged sensitizes bone metastasis to chemotherapy. Cancer Cell 32(6):731–747CrossRefPubMedGoogle Scholar
  4. 4.
    Puisieux A et al (2018) Cellular pliancy and the multistep process of tumorigenesis. Cancer Cell 33(2):164–172CrossRefPubMedGoogle Scholar
  5. 5.
    Banyard J et al (2014) Identification of genes regulating migration and invasion using a new model of metastatic prostate cancer. BMC Cancer 14:387CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Lambert AW, Pattabiraman DR, Weinberg RA (2017) Emerging biological principles of metastasis. Cell 168(4):670–691CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Voon DC et al (2017) The EMT spectrum and therapeutic opportunities. Mol Oncol 11(7):878–891CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Francart ME et al (2018) Epithelial-mesenchymal plasticity and circulating tumor cells: travel companions to metastases. Dev Dyn 247(3):432–450CrossRefPubMedGoogle Scholar
  9. 9.
    Nieto MA et al (2016) Emt: 2016. Cell 166(1):21–45CrossRefPubMedGoogle Scholar
  10. 10.
    Brabletz T et al (2018) EMT in cancer. Nat Rev Cancer 18(2):128–134CrossRefPubMedGoogle Scholar
  11. 11.
    Dalerba P et al (2016) CDX2 as a prognostic Biomarker in stage II and stage III colon cancer. N Engl J Med 374(3):211–222CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Sikandar SS et al (2017) Role of epithelial to mesenchymal transition associated genes in mammary gland regeneration and breast tumorigenesis. Nat Commun 8(1):1669CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Mlecnik B et al (2016) Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 44(3):698–711CrossRefPubMedGoogle Scholar
  14. 14.
    McGranahan N et al (2017) Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171(6):1259–1271CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Thomas F et al (2017) The importance of cancer cells for animal evolutionary ecology. Nat Ecol Evol 1(11):1592–1595CrossRefPubMedGoogle Scholar
  16. 16.
    Pantel K, Alix-Panabieres C (2010) Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med 16(9):398–406CrossRefPubMedGoogle Scholar
  17. 17.
    Bardelli A, Pantel K (2017) Liquid biopsies, what we do not know (Yet). Cancer Cell 31(2):172–179CrossRefPubMedGoogle Scholar
  18. 18.
    Alix-Panabieres C, Pantel K (2016) Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 6(5):479–491CrossRefPubMedGoogle Scholar
  19. 19.
    Alix-Panabieres C, Pantel K (2014) Challenges in circulating tumour cell research. Nat Rev Cancer 14(9):623–631CrossRefPubMedGoogle Scholar
  20. 20.
    Chan KCA et al (2017) Analysis of plasma epstein-barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med 377(6):513–522CrossRefPubMedGoogle Scholar
  21. 21.
    Zhang J, Chen K, Fan ZH (2016) Circulating tumor cell isolation and analysis. Adv Clin Chem 75:1–31CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Muller C et al (2014) Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med 6(247):247ra101CrossRefPubMedGoogle Scholar
  23. 23.
    Boral D et al (2017) Molecular characterization of breast cancer CTCs associated with brain metastasis. Nat Commun 8(1):196CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Ulz P et al (2016) Inferring expressed genes by whole-genome sequencing of plasma DNA. Nat Genet 48(10):1273–1278CrossRefPubMedGoogle Scholar
  25. 25.
    Pantel K, Hayes DF (2018) Disseminated breast tumour cells: biological and clinical meaning. Nat Rev Clin Oncol 15(3):129–131CrossRefPubMedGoogle Scholar
  26. 26.
    Paoletti C et al (2018) Comprehensive mutation and copy number profiling in archived circulating breast cancer tumor cells documents heterogeneous resistance mechanisms. Cancer Res 78(4):1110–1122CrossRefPubMedGoogle Scholar
  27. 27.
    Ferrarini A et al (2018) A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products. PLoS ONE 13(3):e0193689CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Bidard FC et al (2014) Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 15(4):406–414CrossRefPubMedGoogle Scholar
  29. 29.
    Pailler E et al (2017) Circulating tumor cells with aberrant ALK copy number predict progression-free survival during crizotinib treatment in ALK-rearranged non-small cell lung cancer patients. Cancer Res 77(9):2222–2230CrossRefPubMedGoogle Scholar
  30. 30.
    Tie J et al (2016) Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 8(346):346ra92CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Schochter F et al (2018) Endocrine treatment with 2 years of tamoxifen versus 2 years of exemestane in postmenopausal patients with high-risk early breast cancer and persisting circulating tumor cells—first results of the SUCCESS C endocrine treatment sub-study. Oncol Res Treat 41(3):93–98CrossRefPubMedGoogle Scholar
  32. 32.
    Lorente D et al. (2018) Circulating tumor cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. Ann OncolGoogle Scholar
  33. 33.
    Murtaza M et al (2015) Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun 6:8760CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Huang SK, Hoon DS (2016) Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients. Mol Oncol 10(3):450–463CrossRefPubMedGoogle Scholar
  35. 35.
    Mazel M et al (2015) Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol 9(9):1773–1782CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Strati A et al (2017) Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. Ann Oncol 28(8):1923–1933CrossRefPubMedGoogle Scholar
  37. 37.
    Ilie M et al (2018) Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. Ann Oncol 29(1):193–199CrossRefPubMedGoogle Scholar
  38. 38.
    Nicolazzo C et al (2016) Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. Sci Rep 6:31726CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Antonarakis ES et al (2017) Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J Clin Oncol 35(19):2149–2156CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Scher HI et al (2016) Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol 2(11):1441–1449CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Cayrefourcq L et al (2015) Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Res 75(5):892–901CrossRefPubMedGoogle Scholar
  42. 42.
    Baccelli I et al (2013) Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31(6):539–544CrossRefPubMedGoogle Scholar
  43. 43.
    Hodgkinson CL et al (2014) Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med 20(8):897–903CrossRefPubMedGoogle Scholar
  44. 44.
    Amorim MG et al (2017) A total transcriptome profiling method for plasma-derived extracellular vesicles: applications for liquid biopsies. Sci Rep 7(1):14395CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Hoshino A et al (2015) Tumour exosome integrins determine organotropic metastasis. Nature 527(7578):329–335CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Best MG et al (2015) RNA-Seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell 28(5):666–676CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Ramalingam N, Jeffrey SS (2018) Future of liquid biopsies with growing technological and bioinformatics studies: opportunities and challenges in discovering tumor heterogeneity with single-cell level analysis. Cancer J 24(2):104–108CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  1. 1.Laboratory of Rare Human Circulating CellsUniversity Medical Centre of Montpellier, University of MontpellierMontpellierFrance
  2. 2.Department of Tumor BiologyUniversity Medical Centre Hamburg-EppendorfHamburgGermany

Personalised recommendations